Office of the Director, National Institutes of Health; Notice of Meeting, 14223 [06-2728]

Download as PDF Federal Register / Vol. 71, No. 54 / Tuesday, March 21, 2006 / Notices sroberts on PROD1PC70 with NOTICES biology studies, long-range haplotyping, evolutionary studies, centromere analysis and analysis of other regions which cannot be cloned by a routine technique based on in vitro ligation (Kouprina and Larionov (2005) Recent Developments in Nucleic Acids Research, in press). In particular, construction of human artificial chromosome vectors and the combining of a HAC vector with a gene of interest can be effectively performed using the TAR methodology. Human genes isolated by TAR for expression in HACs include HPRT (60kb), BRCA1 (84kb), BRCA2 (90kb), PTEN (120kb), hTERT (60kb), KA11 (200kb), ASPM (70kb), SPANX–C (83kb) among others. TAR is a flexible and efficient means for employing in vivo recombination in yeast in order to clone entire genomic loci which can then be used for structural and functional analysis and for expression in HAC vectors for a variety of uses including for potential use in gene therapy. The TAR cloning Portfolio [HHS Ref. No. E–121–1996/0–US–06 and HHS Ref. No. E–158–2001/0–US–02, U.S. Patent Application Publication No. US2004/ 0248289 filed 04 Oct 2002], including methods of use and vectors, is available for licensing and will be of direct use to those using a functional genomics approach in their work. Related technologies available for licensing also include: the Mammalian Artificial Chromosome Portfolio [HHS Ref. No. E–128–2005/0–US–01, U.S. Provisional Patent Application No. 60/ 669,589 filed 08 Apr 2005 and HHS Ref. No. E–253–2000/0–US–03, U.S. Patent Application Publication No. U.S. 2004/ 0245317 filed April 8, 2002]. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Monoclonal Antibodies Which Specifically Bind to the Ligand Hepatocyte Growth Factor (HGF) and are Useful in the Treatment of Cancer Boliang Cao and George Vande Woude (both of NCI) U.S. Patent Application No. 10/129,596 filed September 30, 2002 (HHS Reference No. E–262–1999/1-US–02), which is a 371 application of PCT/ US00/31036 filed November 9, 2000 and which claims priority to U.S. Provisional Application No. 60/ 164,173 filed November 9, 1999 Licensing Contact: Susan S. Rucker; 301/435–4478; ruckersu@mail.nih.gov. The invention described and claimed in this patent application provides for VerDate Aug<31>2005 19:01 Mar 20, 2006 Jkt 208001 compositions and methods for the treatment of cancers associated with hepatocyte growth factor (HGF). In particular, the patent application describes compositions and methods which employ a combination of monoclonal antibodies which bind to HGF and prevent it from binding to its receptor met in a manner that HGF/met signaling is neutralized. The combination of monoclonal antibodies has been shown to be neutralizing in tumor-bearing nude mice. HGF/met signaling has been most widely studied in settings related to cancer. It has been demonstrated to have a role in metastasis and angiogenesis. In addition to cancer, HGF activity has also been linked, through its role in apoptosis, to Alzheimer’s disease and cardiovascular disease. The application has been published as WO 01/34650 (May 17, 2001). The work has also been published at Cao B, et al PNAS USA 98(13):7443–8 (June 19, 2001) [https://www.pnas.org/cgi/content/ full/98/13/7443]. The hybridomas which can be used to produce the various monoclonal antibodies have been deposited with the ATCC and are available to licensees. Only U.S. Patent protection has been sought for this technology. There are no foreign counterpart patent applications. This application is available for license only. Licenses for the development of therapeutics may be exclusive or nonexclusive. The principal investigators are no longer at the NIH and are not available for NIH collaborative projects under the CRADA mechanism. Dated: March 14, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–4077 Filed 3–20–06; 8:45 am] 14223 reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Office of AIDS Research Advisory Council. Date: April 6–7, 2006. Time: 8:30 a.m. to 1 p.m. Agenda: A Report of the Director addressing OAR initiatives. The topic of the meeting will be addressing prevention research priorities, focusing on microbicides research. Place: Fishers Lane Conference Center, 5635 Fishers Lane, Rockville, MD 20852. Contact Person: Christina Brackna, Executive Secretary, Office of Aids Research, Office of the Director, NIH, 2 Center Drive, MSC 0255, Building 2, Room 4W15, Bethesda, MD 20892. (301) 402–3555. cm53v@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: www.nih.gov/ od/oar/index.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS) BILLING CODE 4140–01–P Dated: March 15, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–2728 Filed 3–20–06; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Director, National Institutes of Health; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Office of AIDS Research Advisory Council. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other PO 00000 Frm 00060 Fmt 4703 Sfmt 4703 National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections E:\FR\FM\21MRN1.SGM 21MRN1

Agencies

[Federal Register Volume 71, Number 54 (Tuesday, March 21, 2006)]
[Notices]
[Page 14223]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-2728]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Office of the Director, National Institutes of Health; Notice of 
Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of 
the Office of AIDS Research Advisory Council.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Office of AIDS Research Advisory Council.
    Date: April 6-7, 2006.
    Time: 8:30 a.m. to 1 p.m.
    Agenda: A Report of the Director addressing OAR initiatives. The 
topic of the meeting will be addressing prevention research 
priorities, focusing on microbicides research.
    Place: Fishers Lane Conference Center, 5635 Fishers Lane, 
Rockville, MD 20852.
    Contact Person: Christina Brackna, Executive Secretary, Office 
of Aids Research, Office of the Director, NIH, 2 Center Drive, MSC 
0255, Building 2, Room 4W15, Bethesda, MD 20892. (301) 402-3555. 
cm53v@nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's/Center's home 
page: www.nih.gov/od/oar/index.htm, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, 
Intramural Research Training Award; 93.22, Clinical Research Loan 
Repayment Program for Individuals from Disadvantaged Backgrounds; 
93.232, Loan Repayment Program for Research Generally; 93.39, 
Academic Research Enhancement Award; 93.936, NIH Acquired 
Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, 
Undergraduate Scholarship Program for Individuals from Disadvantaged 
Backgrounds, National Institutes of Health, HHS)

    Dated: March 15, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-2728 Filed 3-20-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.